SHEL.UK

2,916.5

+3.06%↑

SHEL.UK

2,916.5

+3.06%↑

SHEL.UK

2,916.5

+3.06%↑

SHEL.UK

2,916.5

+3.06%↑

SHEL.UK

2,916.5

+3.06%↑

Search

Smith & Nephew PLC

Gesloten

1,280 -0.74

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1271.5

Max

1292

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

30.5

24.036

EPS

0.429

Dividendrendement

3.07

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+13.87% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.07%

4.19%

Volgende Winsten

2 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.6B

11B

Vorige openingsprijs

1280.74

Vorige sluitingsprijs

1280

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 feb 2026, 23:26 UTC

Belangrijke Marktbewegers

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Winsten

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Winsten

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Marktinformatie
Winsten

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Marktinformatie
Winsten

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Marktinformatie

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Marktinformatie

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Marktinformatie

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Winsten

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Winsten

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Winsten

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Winsten

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Winsten

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Winsten

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Winsten

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Winsten

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Winsten

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Winsten

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Winsten
Acquisities, Fusies, Overnames

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Winsten
Acquisities, Fusies, Overnames

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Winsten

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Winsten

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Winsten

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Winsten
Acquisities, Fusies, Overnames

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Winsten
Acquisities, Fusies, Overnames

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Winsten
Acquisities, Fusies, Overnames

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

13.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,465.5 GBX  13.87%

Hoogste 1,650 GBX

Laagste 1,290 GBX

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat